{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:33:01Z","timestamp":1790137981353,"version":"4.0.1"},"reference-count":94,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zcs250004-1\"><jats:title>Importance<\/jats:title><jats:p>Noonan syndrome (NS) is a rare developmental disorder and the most common condition among the RASopathies. Diagnosis and treatment of NS can be challenging due to the wide phenotypic variability of its manifestations. A multidisciplinary approach is essential, with continuous care required from infancy through adulthood; however, there is a lack of updated and widely shared guidelines for treating this condition.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zcs250004-2\"><jats:title>Objective<\/jats:title><jats:p>To develop consensus statements on the diagnosis of NS, patient transition from pediatric to adult care, follow-up, and treatment of short stature with recombinant human growth hormone (rhGH).<\/jats:p><\/jats:sec><jats:sec id=\"ab-zcs250004-3\"><jats:title>Evidence Review<\/jats:title><jats:p>Consensus was achieved through a modified Delphi process involving a multidisciplinary steering committee comprising 3 pediatric endocrinologists, 1 pediatric cardiologist, 1 molecular geneticist, along with a 25-member expert panel who had expertise in treating NS at clinical reference centers in Italy. In December 2023, the steering committee drafted 47 statements based on published evidence and clinical experience. These statements were then submitted to the expert panel, which provided anonymous feedback on their level of agreement or disagreement between January and March 2024.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zcs250004-4\"><jats:title>Findings<\/jats:title><jats:p>All 25 members of the expert panel completed the Delphi survey and consensus was achieved on all statements after the first round of voting. Full agreement (100%) was reached on several key points: importance of molecular characterization for diagnosis, prognosis, and treatment decisions; necessity of a multidisciplinary approach to NS treatment; need for improved transition from pediatric to adult care; increased risk in patients with hypertrophic cardiomyopathy (HCM); importance of monitoring adherence to rhGH therapy; acknowledgment that partial GH insensitivity should not exclude rhGH therapy; and safety concerns regarding rhGH therapy, particularly related to HCM and the risk of malignant neoplasms.<\/jats:p><\/jats:sec><jats:sec id=\"ab-zcs250004-5\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Effective treatment of NS requires a multidisciplinary and personalized approach from infancy through adulthood. This comprehensive set of consensus statements is intended for clinicians to implement more effective care of patients with NS.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.37603","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:02:09Z","timestamp":1760540529000},"page":"e2537603","source":"Crossref","is-referenced-by-count":6,"title":["Multidisciplinary Treatment of Patients With Noonan Syndrome"],"prefix":"10.1001","volume":"8","author":[{"given":"Stefano","family":"Stagi","sequence":"first","affiliation":[{"name":"Department of Health Sciences, University of Florence, Florence, Italy"},{"name":"Auxo-endocrinology Division, Meyer Children\u2019s Hospital, IRCSS, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cappa","sequence":"additional","affiliation":[{"name":"Research Unit for Innovative Therapies in Endocrinopathies, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Giulia","family":"Gagliardi","sequence":"additional","affiliation":[{"name":"Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Tartaglia","sequence":"additional","affiliation":[{"name":"Molecular Genetics and Functional Genomics, Bambino Ges\u00f9 Children\u2019s Hospital, IRCCS, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Maghnie","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, Genoa, Italy"},{"name":"Department of Pediatrics, Endocrinology Unit, Istituto Giannina Gaslini, IRCCS, Genoa, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Italian Multidisciplinary Noonan Syndrome Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Antoniazzi","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Brambilla","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cappa","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Cattoni","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Cherubini","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"De Luca","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Felicia","family":"Faienza","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Favilli","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Formigari","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Franceschi","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Giacomozzi","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Grandone","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Guazzarotti","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Ibba","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Iughetti","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Limongelli","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Longhi","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Maghnie","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mazzanti","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Pozzobon","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacarolina","family":"Salerno","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Scarano","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Stagi","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Elisabeth","family":"Street","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Tornese","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tyutyusheva","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Vannelli","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata Gabriella","family":"Wasniewska","sequence":"additional","affiliation":[{"name":"for the Italian Multidisciplinary Noonan Syndrome Working Group"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"issue":"4","key":"zcs250004r1","first-page":"373","article-title":"Hypertelorism with Turner phenotype. A new syndrome with associated congenital heart disease.","volume":"116","author":"Noonan","year":"1968","journal-title":"AJDC"},{"issue":"4","key":"zcs250004r2","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1542\/peds.2009-3207","article-title":"Noonan syndrome: clinical features, diagnosis, and management guidelines.","volume":"126","author":"Romano","year":"2010","journal-title":"Pediatrics"},{"issue":"9863","key":"zcs250004r3","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/S0140-6736(12)61023-X","article-title":"Noonan syndrome.","volume":"381","author":"Roberts","year":"2013","journal-title":"Lancet"},{"key":"zcs250004r4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1750-1172-2-4","article-title":"Noonan syndrome.","volume":"2","author":"van der Burgt","year":"2007","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"zcs250004r5","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1038\/gim.2017.249","article-title":"Autosomal recessive Noonan syndrome associated with biallelic LZTR1 variants.","volume":"20","author":"Johnston","year":"2018","journal-title":"Genet Med"},{"issue":"11","key":"zcs250004r6","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1016\/j.ajhg.2021.09.007","article-title":"SPRED2 loss-of-function causes a recessive Noonan syndrome-like phenotype.","volume":"108","author":"Motta","year":"2021","journal-title":"Am J Hum Genet"},{"issue":"4","key":"zcs250004r7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1002\/ajmg.c.32012","article-title":"The molecular genetics of RASopathies: an update on novel disease genes and new disorders.","volume":"190","author":"Tartaglia","year":"2022","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"zcs250004r8","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.beem.2010.09.002","article-title":"Noonan syndrome and clinically related disorders.","volume":"25","author":"Tartaglia","year":"2011","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"zcs250004r9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116060","article-title":"RASopathies: the musculoskeletal consequences and their etiology and pathogenesis.","volume":"152","author":"Fowlkes","year":"2021","journal-title":"Bone"},{"issue":"4","key":"zcs250004r10","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ng772","article-title":"Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.","volume":"29","author":"Tartaglia","year":"2001","journal-title":"Nat Genet"},{"issue":"6","key":"zcs250004r11","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1086\/340847","article-title":"PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity.","volume":"70","author":"Tartaglia","year":"2002","journal-title":"Am J Hum Genet"},{"key":"zcs250004r12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1749-6632.2010.05790.x","article-title":"Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms.","volume":"1214","author":"Tartaglia","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"zcs250004r13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1146\/annurev-genom-091212-153523","article-title":"The RASopathies.","volume":"14","author":"Rauen","year":"2013","journal-title":"Annu Rev Genomics Hum Genet"},{"issue":"1","key":"zcs250004r14","doi-asserted-by":"publisher","first-page":"61.e1","DOI":"10.1016\/j.anpedi.2020.04.008","article-title":"S\u00edndrome de Noonan: actualizaci\u00f3n gen\u00e9tica, cl\u00ednica y de opciones terap\u00e9uticas [Noonan syndrome: genetic and clinical update and treatment options].","volume":"93","author":"Carcavilla","year":"2020","journal-title":"An Pediatr (Engl Ed)"},{"key":"zcs250004r15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1011960","article-title":"Genetic conditions of short stature: a review of three classic examples.","volume":"13","author":"Butler","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"zcs250004r16","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2025.101355","article-title":"Longitudinal outcomes in Noonan syndrome.","volume":"27","author":"Rippert","year":"2025","journal-title":"Genet Med"},{"key":"zcs250004r17","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1566521","article-title":"Editorial: endocrine aspects of Noonan syndrome and related syndromes, volume II.","volume":"16","author":"Mazzanti","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"zcs250004r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2021.104371","article-title":"European medical education initiative on Noonan syndrome: a clinical practice survey assessing the diagnosis and clinical management of individuals with Noonan syndrome across Europe.","volume":"65","author":"Garc\u00eda-Mi\u00f1a\u00far","year":"2022","journal-title":"Eur J Med Genet"},{"issue":"1","key":"zcs250004r21","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004326","article-title":"ACCORD (accurate consensus reporting document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi.","volume":"21","author":"Gattrell","year":"2024","journal-title":"PLoS Med"},{"issue":"5","key":"zcs250004r22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004390","article-title":"Accurate consensus reporting document (ACCORD) explanation and elaboration: guidance and examples to support reporting consensus methods.","volume":"21","author":"Logullo","year":"2024","journal-title":"PLoS Med"},{"issue":"6","key":"zcs250004r23","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s40618-023-02256-4","article-title":"A Delphi panel to build consensus on assessing disease severity and disease progression in adult patients with hypophosphatasia in the United States.","volume":"47","author":"Dahir","year":"2024","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"zcs250004r24","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s13023-021-02083-x","article-title":"Patient engagement in the design of clinical research in Noonan syndrome spectrum disorders: a scoping review.","volume":"16","author":"Tiemens","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"zcs250004r25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies.","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"zcs250004r27","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jclinepi.2019.03.011","article-title":"Delphi procedure in core outcome set development: rating scale and consensus criteria determined outcome selection.","volume":"111","author":"De Meyer","year":"2019","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"zcs250004r28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1471-2288-5-37","article-title":"Stability of response characteristics of a Delphi panel: application of bootstrap data expansion.","volume":"5","author":"Akins","year":"2005","journal-title":"BMC Med Res Methodol"},{"issue":"10","key":"zcs250004r29","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0004867415600891","article-title":"Using the Delphi expert consensus method in mental health research.","volume":"49","author":"Jorm","year":"2015","journal-title":"Aust N Z J Psychiatry"},{"issue":"1","key":"zcs250004r30","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13023-023-02818-y","article-title":"The most important problems and needs of RASopathy patients with a Noonan syndrome spectrum disorder.","volume":"18","author":"Tiemens","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"zcs250004r31","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/ejhg.2012.285","article-title":"Prenatal diagnostic testing of the Noonan syndrome genes in fetuses with abnormal ultrasound findings.","volume":"21","author":"Croonen","year":"2013","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"zcs250004r32","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1002\/pd.4797","article-title":"Retrospective study of prenatal ultrasound findings in newborns with a Noonan spectrum disorder.","volume":"36","author":"Hakami","year":"2016","journal-title":"Prenat Diagn"},{"issue":"6","key":"zcs250004r33","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/s41436-020-01093-7","article-title":"When to test fetuses for RASopathies? Proposition from a systematic analysis of 352 multicenter cases and a postnatal cohort.","volume":"23","author":"Scott","year":"2021","journal-title":"Genet Med"},{"issue":"2","key":"zcs250004r34","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/adc.2006.104547","article-title":"The natural history of Noonan syndrome: a long-term follow-up study.","volume":"92","author":"Shaw","year":"2007","journal-title":"Arch Dis Child"},{"issue":"3","key":"zcs250004r35","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.jpeds.2012.02.043","article-title":"Health and quality of life in adults with Noonan syndrome.","volume":"161","author":"Binder","year":"2012","journal-title":"J Pediatr"},{"key":"zcs250004r36","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1213098","article-title":"Abnormalities of pubertal development and gonadal function in Noonan syndrome.","volume":"14","author":"Patti","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"zcs250004r37","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1312357","article-title":"Undiagnosed RASopathies in infertile men.","volume":"15","author":"Juchnewitsch","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"zcs250004r38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000517605","article-title":"Lymphatic abnormalities in Noonan syndrome spectrum disorders: a systematic review.","volume":"13","author":"Sleutjes","year":"2022","journal-title":"Mol Syndromol"},{"issue":"4","key":"zcs250004r39","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/ajmg.c.32019","article-title":"Management of nutritional and gastrointestinal issues in RASopathies: a narrative review.","volume":"190","author":"Onesimo","year":"2022","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"zcs250004r40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41431-020-00708-6","article-title":"Variants of SOS2 are a rare cause of Noonan syndrome with particular predisposition for lymphatic complications.","volume":"29","author":"Lissewski","year":"2021","journal-title":"Eur J Hum Genet"},{"issue":"11","key":"zcs250004r41","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.3390\/jcm11113128","article-title":"Lymphatic phenotype of Noonan syndrome: innovative diagnosis and possible implications for therapy.","volume":"11","author":"Kleimeier","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"zcs250004r42","doi-asserted-by":"publisher","first-page":"12102","DOI":"10.1038\/s41598-025-90635-7","article-title":"Gene signatures and genotype-phenotype correlations of sensorineural hearing loss in Noonan syndrome and related RASopathies.","volume":"15","author":"Lee","year":"2025","journal-title":"Sci Rep"},{"issue":"8","key":"zcs250004r43","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1007\/s00431-018-3183-1","article-title":"Ocular findings in Noonan syndrome: a retrospective cohort study of 105 patients.","volume":"177","author":"van Trier","year":"2018","journal-title":"Eur J Pediatr"},{"issue":"4","key":"zcs250004r44","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1002\/ajmg.c.32027","article-title":"Dermatological manifestations, management, and care in RASopathies.","volume":"190","author":"Kavamura","year":"2022","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"zcs250004r45","doi-asserted-by":"publisher","DOI":"10.17925\/USE.2008.04.2.93","article-title":"Noonan syndrome\u2014clinical perspectives and growth issues.","author":"Romano","year":"2008","journal-title":"US Endocrinol"},{"issue":"1","key":"zcs250004r46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/ajmg.c.31765","article-title":"Congenital heart defects in Noonan syndrome: diagnosis, management, and treatment.","volume":"184","author":"Linglart","year":"2020","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"2","key":"zcs250004r47","doi-asserted-by":"publisher","first-page":"E7","DOI":"10.1002\/ccd.25324","article-title":"Percutaneous balloon dilation of severe pulmonary valve stenosis in patients with cyanosis and congestive heart failure.","volume":"84","author":"Tefera","year":"2014","journal-title":"Catheter Cardiovasc Interv"},{"issue":"5","key":"zcs250004r48","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1002\/ccd.30148","article-title":"Supravalvular pulmonary stenosis: a risk factor for reintervention in Noonan syndrome with pulmonary valve stenosis.","volume":"99","author":"Abumehdi","year":"2022","journal-title":"Catheter Cardiovasc Interv"},{"issue":"1","key":"zcs250004r49","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.hfc.2021.07.004","article-title":"Hypertrophic cardiomyopathy in RASopathies: diagnosis, clinical characteristics, prognostic implications, and management.","volume":"18","author":"Lioncino","year":"2022","journal-title":"Heart Fail Clin"},{"issue":"2","key":"zcs250004r50","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/ajmg.a.62529","article-title":"Genotype-cardiac phenotype correlations in a large single-center cohort of patients affected by RASopathies: clinical implications and literature review.","volume":"188","author":"Leoni","year":"2022","journal-title":"Am J Med Genet A"},{"issue":"2","key":"zcs250004r51","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/ehf2.14637","article-title":"Natural history and outcomes in paediatric RASopathy-associated hypertrophic cardiomyopathy.","volume":"11","author":"Boleti","year":"2024","journal-title":"ESC Heart Fail"},{"key":"zcs250004r52","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1231828","article-title":"Skeletal defects and bone metabolism in Noonan, Costello and cardio-facio-cutaneous syndromes.","volume":"14","author":"Papadopoulou","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"zcs250004r53","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.thorsurg.2010.07.007","article-title":"Pectus carinatum.","volume":"20","author":"Robicsek","year":"2010","journal-title":"Thorac Surg Clin"},{"issue":"1","key":"zcs250004r54","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1186\/s13023-021-02122-7","article-title":"RASopathies and hemostatic abnormalities: key role of platelet dysfunction.","volume":"16","author":"Di Candia","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"zcs250004r55","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jpeds.2020.01.048","article-title":"The evaluation of hematologic screening and perioperative management in patients with Noonan syndrome: a retrospective chart review.","volume":"220","author":"Briggs","year":"2020","journal-title":"J Pediatr"},{"issue":"4","key":"zcs250004r56","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/ajmg.c.32018","article-title":"Cancer incidence and surveillance strategies in individuals with RASopathies.","volume":"190","author":"Ney","year":"2022","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"12","key":"zcs250004r57","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1158\/1078-0432.CCR-17-0631","article-title":"Recommendations for cancer surveillance in individuals with RASopathies and other rare genetic conditions with increased cancer risk.","volume":"23","author":"Villani","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"21","key":"zcs250004r58","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1158\/1078-0432.CCR-24-1611","article-title":"Update on pediatric cancer surveillance recommendations for patients with neurofibromatosis type 1, Noonan syndrome, CBL syndrome, Costello syndrome, and related RASopathies.","volume":"30","author":"Perrino","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"zcs250004r59","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1007\/s10880-019-09659-7","article-title":"Personality and psychopathology in adults with Noonan syndrome.","volume":"27","author":"Roelofs","year":"2020","journal-title":"J Clin Psychol Med Settings"},{"issue":"16","key":"zcs250004r60","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.3390\/jcm11164735","article-title":"Cognitive phenotype and psychopathology in Noonan syndrome spectrum disorders through various Ras\/MAPK pathway associated gene variants.","volume":"11","author":"Wingberm\u00fchle","year":"2022","journal-title":"J Clin Med"},{"key":"zcs250004r61","first-page":"31","article-title":"Growth in Noonan syndrome.","volume":"72","author":"Otten","year":"2009","journal-title":"Horm Res"},{"issue":"1","key":"zcs250004r62","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/MED.0000000000000380","article-title":"Noonan syndrome: an update on growth and development.","volume":"25","author":"Yart","year":"2018","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"4","key":"zcs250004r63","doi-asserted-by":"publisher","first-page":"240","DOI":"10.6065\/apem.2017.22.4.240","article-title":"Development of disease-specific growth charts in Turner syndrome and Noonan syndrome.","volume":"22","author":"Isojima","year":"2017","journal-title":"Ann Pediatr Endocrinol Metab"},{"key":"zcs250004r64","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.691240","article-title":"Etiology and treatment of growth delay in Noonan syndrome.","volume":"12","author":"Rodr\u00edguez","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"zcs250004r65","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.3390\/jcm11072034","article-title":"Growth, endocrine features, and growth hormone treatment in Noonan syndrome.","volume":"11","author":"Dahlgren","year":"2022","journal-title":"J Clin Med"},{"issue":"1","key":"zcs250004r66","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1038\/s41467-021-21712-4","article-title":"Activating mutations in BRAF disrupt the hypothalamo-pituitary axis leading to hypopituitarism in mice and humans.","volume":"12","author":"Gualtieri","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"zcs250004r67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000502231","article-title":"Diagnosis, genetics, and therapy of short stature in children: a growth hormone research society international perspective.","volume":"92","author":"Collett-Solberg","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"zcs250004r68","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.951331","article-title":"Inside the Noonan \u201cuniverse\u201d: literature review on growth, GH\/IGF axis and rhGH treatment: facts and concerns.","volume":"13","author":"Stagi","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"zcs250004r69","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1210\/clinem\/dgac517","article-title":"Safety and efficacy of pediatric growth hormone therapy: results from the full KIGS cohort.","volume":"107","author":"Maghnie","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"zcs250004r70","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2023.101532","article-title":"Efficacy and safety of growth hormone therapy in children with Noonan syndrome.","volume":"69-70","author":"Sodero","year":"2023","journal-title":"Growth Horm IGF Res"},{"issue":"5","key":"zcs250004r71","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1210\/er.2017-00232","article-title":"The RASopathy family: consequences of germline activation of the RAS\/MAPK pathway.","volume":"39","author":"Tajan","year":"2018","journal-title":"Endocr Rev"},{"issue":"1","key":"zcs250004r72","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ajmg.a.20502","article-title":"Adult height in Noonan syndrome.","volume":"123A","author":"Noonan","year":"2003","journal-title":"Am J Med Genet A"},{"key":"zcs250004r73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000540092","article-title":"Noonan syndrome growth charts and genotypes: 15-year longitudinal single-centre study.","volume":"22","author":"Cappa","year":"2024","journal-title":"Horm Res Paediatr"},{"key":"zcs250004r74","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.795224","article-title":"Treatment adherence to injectable treatments in pediatric growth hormone deficiency compared with injectable treatments in other chronic pediatric conditions: a systematic literature review.","volume":"13","author":"Gomez","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"zcs250004r75","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264403","article-title":"Pediatric growth hormone treatment in Italy: a systematic review of epidemiology, quality of life, treatment adherence, and economic impact.","volume":"17","author":"Orso","year":"2022","journal-title":"PLoS One"},{"issue":"6","key":"zcs250004r76","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1515\/jpem-2022-0045","article-title":"Global perspective on pediatric growth hormone registries: a systematic review.","volume":"35","author":"Eslami","year":"2022","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"3","key":"zcs250004r77","doi-asserted-by":"publisher","first-page":"182","DOI":"10.6065\/apem.1938154.077","article-title":"Effectiveness of growth hormone therapy in children with Noonan syndrome.","volume":"25","author":"Seok","year":"2020","journal-title":"Ann Pediatr Endocrinol Metab"},{"issue":"6","key":"zcs250004r78","doi-asserted-by":"publisher","first-page":"592","DOI":"10.5603\/ep.101588","article-title":"Management strategies for optimal linear growth in Noonan syndrome (NS) children: minireview and case series of three patients with NS due to PTPN11 mutation and confirmed growth hormone deficiency.","volume":"75","author":"Kowalik","year":"2024","journal-title":"Endokrynol Pol"},{"issue":"4","key":"zcs250004r79","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4274\/jcrpe.galenos.2022.2022-12-13","article-title":"The effect of growth hormone therapy on cardiac outcomes in Noonan syndrome: long term follow-up results.","volume":"14","author":"Kizilcan \u00c7etin","year":"2022","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"1","key":"zcs250004r80","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1046\/j.1365-2265.2001.01188.x","article-title":"Growth hormone (GH) secretion in children with Noonan syndrome: frequently abnormal without consequences for growth or response to GH treatment.","volume":"54","author":"Noordam","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"zcs250004r81","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ecl.2012.07.002","article-title":"Safety of growth hormone treatment in patients previously treated for cancer.","volume":"41","author":"Chemaitilly","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"6","key":"zcs250004r82","doi-asserted-by":"publisher","first-page":"P35","DOI":"10.1530\/EJE-21-1186","article-title":"Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement.","volume":"186","author":"Boguszewski","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"zcs250004r83","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2021.104372","article-title":"Management of cardiac aspects in children with Noonan syndrome\u2014results from a European clinical practice survey among paediatric cardiologists.","volume":"65","author":"Wolf","year":"2022","journal-title":"Eur J Med Genet"},{"issue":"1","key":"zcs250004r84","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2021.104404","article-title":"Management of growth failure and other endocrine aspects in patients with Noonan syndrome across Europe: a sub-analysis of a European clinical practice survey.","volume":"65","author":"Edouard","year":"2022","journal-title":"Eur J Med Genet"},{"key":"zcs250004r85","doi-asserted-by":"publisher","DOI":"10.4274\/jcrpe.galenos.2025.2024-9-13","article-title":"Noonan syndrome, cancer risk, and growth hormone treatment.","author":"Demir","year":"2025","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"6","key":"zcs250004r86","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1159\/000479107","article-title":"Occurrence of cranial neoplasms in pediatric patients with Noonan syndrome receiving growth hormone: is screening with brain MRI prior to initiation of growth hormone indicated?","volume":"88","author":"Bangalore Krishna","year":"2017","journal-title":"Horm Res Paediatr"},{"issue":"8","key":"zcs250004r87","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1507\/endocrj.EJ19-0371","article-title":"Long-term efficacy and safety of two doses of Norditropin\u00ae (somatropin) in Noonan syndrome: a 4-year randomized, double-blind, multicenter trial in Japanese patients.","volume":"67","author":"Horikawa","year":"2020","journal-title":"Endocr J"},{"issue":"12","key":"zcs250004r88","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1136\/archdischild-2021-322858","article-title":"Noonan syndrome: improving recognition and diagnosis.","volume":"107","author":"Zenker","year":"2022","journal-title":"Arch Dis Child"},{"issue":"1","key":"zcs250004r89","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13023-025-03594-7","article-title":"Health outcomes and drug utilisation in children with Noonan syndrome: a European cohort study.","volume":"20","author":"Santoro","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"zcs250004r94","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/0040-1625(91)90002-W","article-title":"An evaluation of Delphi.","volume":"40","author":"Woudenberg","year":"1991","journal-title":"Technol Forecast Soc Change"},{"key":"zcs250004r18","unstructured":"Noonan Syndrome Guideline Development Group. Management of Noonan syndrome: a clinical guideline. Published February 15, 2010. Accessed December 6, 2024. https:\/\/rasopathiesnet.org\/wp-content\/uploads\/2014\/01\/265_Noonan_Guidelines.pdf"},{"key":"zcs250004r19","unstructured":"National Organization for Rare Disorders (NORD). Noonan syndrome. Updated August 21, 2019. Accessed December 6, 2024. https:\/\/rarediseases.org\/rare-diseases\/noonan-syndrome\/"},{"key":"zcs250004r26","unstructured":"Oxford Centre for Evidence-Based Medicine. Oxford Center for Evidence Based Medicine: levels of evidence (March 2009). Published March 2009. Accessed September 10, 2025. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009"},{"key":"zcs250004r90","unstructured":"Italian Medicines Agency. Nota 39. Published March 28, 2023. Accessed December 10, 2024. https:\/\/www.aifa.gov.it\/documents\/20142\/1728041\/nota-39.pdf"},{"key":"zcs250004r91","unstructured":"UK Medicines and Healthcare Products Regulatory Agency. UK Norditropin summary of product characteristics. Updated September 20, 2024. Accessed December 10, 2024. https:\/\/www.medicines.org.uk\/emc\/product\/11757\/smpc\/print"},{"key":"zcs250004r92","unstructured":"U.S. Food and Drug Administration. FDA Norditropin highlights of prescribing information. Updated February 2018. Accessed December 10, 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021148s053lbl.pdf"},{"key":"zcs250004r93","unstructured":"France Haute Autorit\u00e9 de Sant\u00e9. Norditropine, somatropine. Published November 3, 2020. Accessed December 10, 2024. https:\/\/www.has-sante.fr\/jcms\/p_3214282\/fr\/norditropine-somatropine-somatropine"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2840145\/stagi_2025_cs_250004_1759861266.10482.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:02:14Z","timestamp":1760540534000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2840145"}},"subtitle":["A Consensus Statement"],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":94,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.37603","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]}}}